企业负责人陈国利表示，海南封关之后，他第一时间就到了海口，如果这个资金到位，2026年他们能够形成2到3亿元的装备产值， 机遇很多，更加有信心在这里落地生根、发展壮大。 E CCTV 1 CCTV Com 编 ロロ HEN NEW 111 E CETV D CETN COM Paccunante smanning .. : # ab 区 CCTV/ 奥视网 COM MI 综合 nggeneral 在海南，各行各业都展现了热气腾腾的新气象。新年以来，海南游客数量激增。网络出行平台数据显示，新年第一周（1日—7 日），三亚、海口入境游客分别增长28%和15%，吸引大量来自韩国、泰国、马来西亚、新加坡和澳大利亚等国家的旅客。 央视网消息：2026年是海南自贸港封关后的第一年，自贸港正在积极开启奋斗新征程，各行各业都在抢抓封关后的政策新机遇，打 造发展的新热土。 新年伊始，海南就从"十五五"重点发展领域里挑选了上百个优质项目向各界开放。涵盖了全海南18个市县，涉及低空经济、热带农 业等诸多领域，吸引了大批企业纷至沓来。 外国游客表示，中国非常开放，他们从马来西亚到海南是免签的，买一张机票就可以了，非常方便。 外国游客 ...

Core Viewpoint - Haier Biomedical has received a report from Qindao Jiushi Investment Management Co., indicating that Jiushi Youxuan No. 1 Fund plans to increase its stake in the company by 15,897,909 shares, representing 5.00% of the total share capital, due to a long-term positive outlook on the life sciences industry and recognition of Haier Biomedical's performance in governance, industry position, business capabilities, operational results, and risk management [1][2]. Group 1 - Jiushi Youxuan No. 1 Fund is currently the second-largest circulating shareholder of Yinkang Life, showcasing its strategic focus on the medical technology sector and recognition of Haier Biomedical's solid fundamentals and clear growth logic [2]. - Haier Biomedical, a leader in low-temperature storage equipment in the biomedical sector, achieved a net profit of 143 million yuan in the first half of 2025, with new industry revenue accounting for 47% of total revenue, driving performance growth [2]. - The company has established a collaborative development framework across four major industries: low-temperature storage, smart medication, blood technology, and laboratory solutions, with significant market shares in various segments [2]. Group 2 - Haier Group, the actual controller of Haier Biomedical, has recently formed a comprehensive strategic partnership with Ant Group to promote the digital upgrade of healthcare services, positioning Haier Biomedical for new growth opportunities [3]. - The investment from Jiushi Youxuan No. 1 Fund is seen as a recognition of Haier Biomedical's technological barriers and growth potential, which may boost investor confidence and provide stronger momentum for the company's long-term development [3].

Fundraising Overview - The company raised a total of RMB 1,156,905,698.60 after deducting issuance costs of RMB 4,670,375.54, with the net amount available for use being RMB 1,156,905,698.60 [1][4] - As of June 30, 2025, the company had utilized RMB 1,029,056,832.19 for fundraising projects, with a remaining balance of RMB 52,258.70 [1][4] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure proper use and management of the funds [1][2] - A tripartite agreement for the special account storage of fundraising was signed with Guotai Junan Securities and Bank of China, ensuring dedicated management of the funds [2][3] Fund Usage - The company has not used any idle funds for working capital during the reporting period, and all funds have been allocated according to the approved projects [4][6] - The company approved the use of RMB 15,000,000 of temporarily idle funds for cash management, with a maximum of RMB 4,700,000 allocated for permanent working capital [5][8] Compliance and Reporting - The company has adhered to all legal and regulatory requirements regarding the use of fundraising, with no violations reported [6][7] - The board of directors and supervisory board confirmed that the information disclosed regarding the fundraising usage is timely, accurate, and complete [7][9]

Core Viewpoint - The company, Qingdao Haier Biomedical Co., Ltd., is set to hold a half-year performance briefing on August 28, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in a Q&A session [2][3]. Group 1: Meeting Details - The performance briefing will take place on August 28, 2025, from 13:00 to 14:00 [5]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [4][5]. - Investors can submit questions from August 21 to August 27, 2025, through the Roadshow Center website or via the company's email [6]. Group 2: Participation Information - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [4][5]. - The company will address commonly asked questions during the briefing, ensuring transparency and engagement with investors [3][6]. - Contact information for the company's securities department is provided for further inquiries [6].

Core Viewpoint - The company has adjusted the maximum repurchase price of its shares from RMB 50.00 per share to RMB 49.5367 per share following the implementation of the 2024 annual profit distribution plan [1][2][3] Summary by Sections 1. Basic Information on Share Repurchase - The company plans to repurchase its shares using its own funds through the Shanghai Stock Exchange, with a total repurchase amount between RMB 100 million and RMB 200 million within 12 months from the board's approval date [1] 2. Reasons for Adjusting the Maximum Repurchase Price - The adjustment is due to the company's decision to distribute a cash dividend of RMB 4.7 per 10 shares to all shareholders, which affects the base for calculating the repurchase price [2][3] 3. Details of the Price Adjustment - The new maximum repurchase price is calculated as follows: (previous maximum price - cash dividend per share) / (1 + change in circulating shares ratio). The cash dividend per share is approximately RMB 0.4633 based on the total shares participating in the distribution [3] 4. Estimated Repurchase Quantity - With the adjusted maximum repurchase price of RMB 49.5367, the company estimates it can repurchase approximately 4.0374 million shares, representing about 1.27% of the total share capital, based on the upper limit of RMB 200 million [4] 5. Other Matters - Other aspects of the share repurchase plan remain unchanged, and the company will adhere to relevant regulations while making repurchase decisions based on market conditions [5]